Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy

Background NR2F6 has been proposed as an alternative cancer immune checkpoint in the effector T cell compartment. However, a realistic assessment of the in vivo therapeutic potential of NR2F6 requires acute depletion.